Day One Biopharmaceuticals Inc (OQ:DAWN)
Business Focus: Biotechnology & Medical Research
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 395 Oyster Point Blvd Ste 217 SOUTH SAN FRANCISCO CA 94080-1930 |
| Tel: | N/A |
| Website: | https://dayonebio.com |
| IR: | See website |
| Key People | ||
| Julie Grant Chairman of the Board, Co-Founder | Jeremy Bender President, Chief Executive Officer, Director | Samuel Blackman Co-Founder, Chief Medical Officer | Charles N. York Chief Financial Officer, Chief Operating Officer, Secretary |
| Business Overview |
| Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers. It seeks to identify, acquires, and develops product candidates that target high-value oncogenic drivers in cancers with unmet need, with an initial focus on pediatric patients. Its lead product candidate, DAY101 (tovorafenib), is an oral, brain-penetrant, highly selective type II pan-rapidly accelerated fibrosarcoma (pan-RAF), kinase inhibitor. Tovorafenib is also used for the treatment of low-grade gliomas (LGGs). Its second product candidate, pimasertib, is an oral, highly selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a key signaling node in the MAPK pathway. It has initiated a phase II trial of tovorafenib for pediatric patients with relapsed or progressive low-grade glioma (pLGG), the common brain tumor diagnosed in children. |
| Financial Overview |
| For the six months ended 30 June 2022, Day One Biopharmaceuticals Inc revenues was not reported. Net loss decreased 50% to $64.3M. Lower net loss reflects Other expense decrease of 97% to $1K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.10 to -$1.08. |
| Employees: | 94 as of Jun 30, 2022 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $1,276M as of Jun 30, 2022 |
| Annual revenue (TTM): | $0.00M as of Jun 30, 2022 |
| EBITDA (TTM): | -$105.66M as of Jun 30, 2022 |
| Net annual income (TTM): | -$105.46M as of Jun 30, 2022 |
| Free cash flow (TTM): | -$76.76M as of Jun 30, 2022 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 73,461,100 as of Aug 1, 2022 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2022 INK Research Corp. All rights reserved.
US Quotes Data provided by IEX. US Quotes Data provided by IEX. Company fundamental sourced from © Refinitiv. Click for restrictions. © Refinitiv. All rights reserved. Republication or redistribution of Refinitiv, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. Refinitiv is not liable for any errors or delays in Refinitiv content, or for any actions taken in reliance on such content.
US Quotes Data provided by IEX. US Quotes Data provided by IEX. Company fundamental sourced from © Refinitiv. Click for restrictions. © Refinitiv. All rights reserved. Republication or redistribution of Refinitiv, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. Refinitiv is not liable for any errors or delays in Refinitiv content, or for any actions taken in reliance on such content.